New sequencing approaches, such as next-generation sequencing (NGS), have more clinical utility compared to conventional genetic testing tools, particularly for rare cancers. The increased sensitivity of such approaches also leads to an overwhelming amount of data being generated on genetic variants. When it comes to making sense of sequencing date, you want the following:
- Reliable annotations for each variant
- All of the known literature associated with a given variant
- Database curation by expert oncologists and scientists
Such a database can help clinical lab professionals and clinicians understand the biological relevance and therapeutic actionability of patients' genetic profiles in rare cancers. Powerful software like QCI Interpret One does all of that to help understand the prognosis, diagnosis, and therapeutic options available for individuals with rare cancers.